This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cardinal Health Stock Likely to Gain From the Acquisition of ION
by Zacks Equity Research
CAH is set to acquire Oncology Network for $1.115 billion, expanding its oncology offerings while supporting community-based cancer care across 10 states.
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Applied Therapeutics Inc. (APLT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Cardinal Health (CAH) reachead $110.76 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.
CAH Stock May Gain Following the Distribution Agreement With Telix
by Zacks Equity Research
Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Cardinal Health (CAH) Gained But Lagged the Market Today
by Zacks Equity Research
In the latest trading session, Cardinal Health (CAH) closed at $113.28, marking a +0.1% move from the previous day.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health (CAH) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
The latest trading day saw Cardinal Health (CAH) settling at $112.80, representing a +0.92% change from its previous close.
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Greenville Center to Boost CAH Stock's at-Home Solution Business
by Zacks Equity Research
Cardinal Health announces the opening of its new distribution center in Greenville to support its at-Home Solutions business.
Zacks Investment Ideas feature highlights: Cardinal Health, Taiwan Semiconductor and Altria
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Cardinal Health, Taiwan Semiconductor and Altria.
3 Consistent Dividend Growers to Buy for Passive Income: TSM, MO, CAH
by Derek Lewis
For those seeking companies with a consistent history of steady payouts, all three of these stocks fit the criteria. Who doesn't like payday?
Cardinal Health (CAH) to Open New Distribution Center in Ohio
by Zacks Equity Research
Cardinal Health's (CAH) new center is set to integrate cutting-edge technology and automation, enhancing efficiency, storage capacity and quality of service.
Zacks Investment Ideas feature highlights: Walmart, Cardinal Health and Eli Lilly
by Zacks Equity Research
Walmart, Cardinal Health and Eli Lilly have been highlighted in this Investment Ideas article.
3 Companies Reporting Remarkable Results: WMT, LLY, CAH
by Derek Lewis
All three companies posted robust results and upped their outlooks, a bullish pairing. Is it time to buy?
Company News for Aug 15, 2024
by Zacks Equity Research
Companies in The News Are: CAH,UBS,EAT,ESLT
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Here's What Key Metrics Tell Us About Cardinal (CAH) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 6.98% and 1.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Seeking Clues to Cardinal (CAH) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Cardinal (CAH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of -500% and 2.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?